索利那新联合坦索罗辛治疗经尿道前列腺电切术后膀胱过度活动症临床效果观察

目的：探讨索利那新联合坦索罗辛治疗经尿道前列腺电切术后膀胱过度活动症的临床效果。方法：选取2011年1月～2012年6月来我院进行经尿道前列腺电切术后出现膀胱过度活动症的患者48例，随机分为对照组和观察组，观察组给予索利那新5mg、坦索罗辛O．2rag，口服，1次／d，连续1周。对照组仅于疼痛时给予吲哚美辛栓剂对症治疗。治疗前后对两组患者进行膀胱过度活动症评分、生活质量评分及前列腺症状评分，评价药物的疗效及副反应发生情况。结果：48例患者均在住院部完成治疗，观察组用药时间约为7—10d，平均8．5d，待患者尿失禁、尿频等症状消失后停药。治疗前两组的OABSS评分、QOL评分、IPSS评分间无显著性差异（P〉0．05），治疗后观察组的OABSS评分、QOL评分、IPSS评分均明显低于对照组，且存在显著性差异（P〈0．05）。观察组与治疗前比较，存在显著性差异，对照组三项评分与治疗前比较，无显著差异。观察组患者中仅1例出现口干症状，未见头晕、便秘、头痛等不良反应，其余患者未出现不良反应。结论：索利那新联合坦索罗辛用于治疗经尿道前列腺电切术后膀胱过度症疗效显著，可显著改善膀胱过度症状，不良反应低，值得临床推广应用。

Clinical effects of Solifenacin combined with Tamsulosin in treating overactive bladder after transurethral resection prostate

Objectives： To study the clinical effect of Solifenaein combined with Tamsulosin in the treatment of overactive bladder after transurethral resection prostate（TURP）. Methods： We selected 48 patients with overactive bladder after TURP in our hospital from January 2011 to June 2012. They were divided into control group and observation group randomly. The patients in the observation group were treated with 5mg of Solifenacin and 0.2rag of Tamsulosin orally once a day and the course lasts for seven to ten days. The patients in the control group only got indomethacin suppository, symptomatic treatment when they were in pain. We assessed the overactive bladder syndrome, the quality of life and the international prostate symptom of the two groups before and after the treatment to evaluate the therapeutic efficacy and side effects of the drugs. Results ： All the patients finished the treatment in the inpatient department. For the observation group, the drug taking course is seven to ten days, 8. 5 days in av- erage. The drug was suspended after the symptoms of frequent micturition and urinary incontinence disappear. Before receiving the treatment, there is no significant difference of the OABSS score, QOL score and IPSS score of the two groups. （ P 〉 O. 05 ） After treatment, the OABSS score, QOL score, IPSS score of observation group are significantly lower than those of the control group. （ P 〈 0.05 ） The scores changed greatly before and after the treatment while there is no significant difference in the control group （ P 〉 0. 05 ）. Only one patient of the observation group has dry mouth symptom, and without other adverse reactions such as the dizziness, constipation, headaches. The rest patients have no adverse reactions. Conclusions： Solifenacin combined with Ta- msnlosin can be adopted in the treatment of overactive bladder after transurethral resection prostate, and the curative effect is out- standing. It can significantly improve the bladder excessive symptom, having lower rate of adverse reactions.